Key features and details
- Expression system: Escherichia coli
- Purity: > 95% SDS-PAGE
- Active: Yes
- Suitable for: SDS-PAGE, Functional Studies
製品名Recombinant mouse PAI1 (mutated I91) protein
PAI1 タンパク質・ペプチド 製品一覧
ab93066 is 95 (+/-) 5% active by uPA titration; half-life at 37°C, pH 7.4 is ~18 hours.
精製度> 95 % SDS-PAGE.
タンパク質長Full length protein
Our Abpromise guarantee covers the use of ab93066 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Concentration information loading...
Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.
Constituents: 0.41% Sodium acetate, 0.0292% EDTA, 0.58% Sodium chloride
This product is an active protein and may elicit a biological response in vivo, handle with caution.
- Clade E
- Endothelial plasminogen activator inhibitor
機能This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis.
組織特異性Found in plasma and platelets and in endothelial, hepatoma and fibrosarcoma cells.
関連疾患Defects in SERPINE1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1D) [MIM:613329]. It is a hematologic disorder characterized by increased bleeding after trauma, injury, or surgery. Affected females have menorrhagia. The bleeding defect is due to increased fibrinolysis of fibrin blood clots due to deficiency of plasminogen activator inhibitor-1, which inhibits tissue and urinary activators of plasminogen.
Note=High concentrations of SERPINE1 seem to contribute to the development of venous but not arterial occlusions.
配列類似性Belongs to the serpin family.
翻訳後修飾Inactivated by proteolytic attack of the urokinase-type (u-PA) and the tissue-type (TPA), cleaving the 369-Arg-
- Information by UniProt
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.